

ISO 13022:2012-04 (E)

Medical products containing viable human cells - Application of risk management and requirements for processing practices

Contents		Page
Foreword		iv
Introduction		v
1	Scope	1
2	Normative references	2
3	Terms and definitions	2
4	Risk management process	6
4.1	General	6
4.2	Hazards associated with the cellular component	6
4.3	Risk analysis	8
4.4	Risk evaluation	9
4.5	Risk control	9
4.6	Evaluation of overall residual risk acceptability	9
4.7	Production and post-production information system	10
Annex B (informative) Graphic representation of the part of the risk management process for cell-based medical products		12
Annex C (normative) Requirements for donor selection and testing		13
Annex D (informative) Guidance for tissue procurement		17
Annex E (normative) Requirements for handling of cells and tissue during manufacture		20
Annex F (normative) Requirements for packaging and labelling		23
Annex G (informative) Guidance for transport		26
Annex H (informative) Guidance for storage		31
Annex I (normative) Requirements for traceability		34
Annex J (normative) Risk reduction measures relating to contamination with viruses and other infectious agents such as TSE		35
Annex K (informative) Guidance relating to hazards caused by the tumorigenic potential of human cells or tissues used for the production of medical products		38
Annex L (informative) Guidance relating to microbiological contamination		39
Annex M (informative) Guidance relating to potential adverse effects of non-cellular residues of the product		40
Annex N (normative) Requirements relating to potential adverse effects of the cellular components of a medical product		41

Annex O (informative) Guidance for the characterization of the cellular components of a medical product	42
Annex P (informative) Clinical evaluation and testing	45
Bibliography	46